GAMMA Investing LLC Has $160,000 Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

GAMMA Investing LLC cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 16.9% in the 4th quarter, HoldingsChannel reports. The fund owned 865 shares of the medical research company’s stock after selling 176 shares during the quarter. GAMMA Investing LLC’s holdings in Charles River Laboratories International were worth $160,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the period. State Street Corp raised its stake in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of Charles River Laboratories International by 1.7% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock valued at $394,359,000 after buying an additional 31,359 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after purchasing an additional 509,163 shares during the last quarter. Finally, Earnest Partners LLC lifted its position in shares of Charles River Laboratories International by 12.4% during the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock worth $207,507,000 after buying an additional 110,725 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price on the stock. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a report on Monday, November 18th. TD Cowen increased their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Robert W. Baird reduced their price target on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, September 20th. Finally, Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $214.00.

Charles River Laboratories International Price Performance

CRL stock opened at $187.74 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $9.60 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 5.00 and a beta of 1.38. The company’s fifty day simple moving average is $193.13 and its 200 day simple moving average is $199.79. Charles River Laboratories International, Inc. has a 12-month low of $176.48 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter last year, the firm posted $2.72 earnings per share. The firm’s revenue was down 1.6% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Insider Activity

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).